Submit Answers

Australian Pharmacist logo

August 2019

The below online CPD modules from the current edition of Australian Pharmacist are available free for PSA members.

New injectable therapies for diabetes – Practical considerations

The article presents emerging injectable therapies for type 2 diabetes that are more effective or more convenient for users. They include longer-acting glucagon-like peptide analogues with better HbA1c lowering ability and a more user-friendly injection device, longer-acting once daily insulins, and a higher dose insulin glargine with a small injection volume.

Hay fever

Allergic rhinitis (commonly known as hay fever) a­ffects approximately 18% of people in Australia and New Zealand. Hay fever can cause significant disruption to the lives of those a­ffected, particularly those with moderate-to-severe symptoms. It can have a significant impact on learning and daily function and a­ffect childhood behaviour and development. Yet it is commonly underdiagnosed, undertreated and sub-optimally self-managed. Pharmacists have a role in helping people effectively manage and treat hay fever and its symptoms.

Asthma in children

Asthma is a common, chronic inflammatory disease of the airways that presents as episodes of wheezing, breathlessness, cough and chest tightness. It is due to widespread narrowing of the airways and obstruction of airflow. Among children aged 5–14 years, asthma is the leading cause of burden of disease in Australia.

Mild cognitive impairment, dementia and Alzheimer’s disease – The basics

In Australia this year, there are almost half a million people living with dementia. In older Australians (65 years and older), it is the single greatest cause of disability and the third leading cause of disability burden overall.4 In 2016, dementia was the second leading cause of death, surpassing heart disease.

Past journals

PSA members can view articles and submit answers to assessment questions from Australian Pharmacist CPD from the previous 24 months by clicking the links below.